Literature DB >> 4759936

BCG immunotherapy of a rat sarcoma.

R W Baldwin, M V Pimm.   

Abstract

Growth of syngeneic transplants of a 3-methylcholanthrene induced rat sarcoma was suppressed when tumour cells were injected in admixture with BCG. Rejection of these mixed inocula resulted in the suppression of growth of a simultaneous challenge with cells of the same tumour at a contralateral subcutaneous site and conditions for immunotherapy were evaluated with respect to the maximum tumour cell challenge rejected and the optimum time of treatment. These studies established that viable tumour cells were more effective than radiation attenuated cells for the immunizing stimulus. Also, the maximum tumour challenge totally rejected in this way was of the order of 10(6) cells, and with this rapidly growing tumour, treatment had to be initiated within 4 days of tumour injection. These observations are relevant to current proposals for adjuvant immunotherapy of human malignant disease where conditions of minimal residual disease are not being fulfilled.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4759936      PMCID: PMC2008907          DOI: 10.1038/bjc.1973.149

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  Suppression of murine tumor growth by immune reaction to the Bacillus Calmette-Guérin strain of Mycobacterium bovis.

Authors:  G L Bartlett; B Zbar; H J Rapp
Journal:  J Natl Cancer Inst       Date:  1972-01       Impact factor: 13.506

2.  Tumor-specific vaccine containing Mycobacterium bovis and tumor cells: safety and efficacy.

Authors:  G L Bartlett; B Zbar
Journal:  J Natl Cancer Inst       Date:  1972-06       Impact factor: 13.506

3.  Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis.

Authors:  B Zbar; I D Bernstein; G L Bartlett; M G Hanna; H J Rapp
Journal:  J Natl Cancer Inst       Date:  1972-07       Impact factor: 13.506

4.  Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin.

Authors:  B Zbar; I D Bernstein; H J Rapp
Journal:  J Natl Cancer Inst       Date:  1971-04       Impact factor: 13.506

5.  Influence of BCG infection on growth of 3-methylcholanthrene-induced rat sarcomas.

Authors:  R W Baldwin; M V Pimm
Journal:  Rev Eur Etud Clin Biol       Date:  1971-11

6.  Active immunotherapy with Corynebacterium parvum and chemotherapy in murine fibrosarcomas.

Authors:  G A Currie
Journal:  Br Med J       Date:  1970-02-28

7.  Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells.

Authors:  G Mathé; P Pouillart; F Lapeyraque
Journal:  Br J Cancer       Date:  1969-12       Impact factor: 7.640

8.  Inhibitory effect of injection of Corynebacterium parvum on the growth of tumour transplants in isogenic hosts.

Authors:  M F Woodruff; J L Boak
Journal:  Br J Cancer       Date:  1966-06       Impact factor: 7.640

9.  BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells.

Authors:  R W Baldwin; M V Pimm
Journal:  Br J Cancer       Date:  1973-01       Impact factor: 7.640

10.  Response of syngeneic murine lymphomata to immunotherapy in relation to the antigenicity of the tumour.

Authors:  I Parr
Journal:  Br J Cancer       Date:  1972-06       Impact factor: 7.640

View more
  20 in total

1.  Controlled trial of active immunotherapy in management of stage IIB malignant melanoma.

Authors:  M B McIllmurray; M J Embleton; W G Reeves; M J Langman; M Deane
Journal:  Br Med J       Date:  1977-02-26

2.  Current status of immunotherapy.

Authors:  A Coates
Journal:  Drugs       Date:  1974       Impact factor: 9.546

3.  Immunotherapy: its possible application in the management of large-bowel cancer.

Authors:  G M Mavligit; J U Guttermann; M A Burgess; J F Speer; R C Reed; R C Martin; C M McBride; E M Copeland; E A Gehan; E M Hersh
Journal:  Am J Dig Dis       Date:  1974-11

Review 4.  Immunology of bronchial carcinoma.

Authors:  D A Evans
Journal:  Thorax       Date:  1976-10       Impact factor: 9.139

Review 5.  Manipulation of host resistance in cancer therapy.

Authors:  R W Baldwin
Journal:  Springer Semin Immunopathol       Date:  1982

6.  Immunological aspects of gliomas.

Authors:  A Ridley
Journal:  Proc R Soc Med       Date:  1977-12

7.  Circulating immune complexes detected by 125I-Clq deviation test in sera of cancer patients.

Authors:  H Teshima; H Wanebo; C Pinsky; N K Day
Journal:  J Clin Invest       Date:  1977-06       Impact factor: 14.808

8.  The therapeutic effects of an immunopotentiator, PS-K, on 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary sites.

Authors:  M Hosokawa; T Mizukoshi; K Morikawa; Z Y Xu; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Immunogenicity of cellular and acellular antigen preparations from a methylcholanthrene-induced mouse sarcoma.

Authors:  K Höffken; U Steih; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

10.  Effect of cisplatin upon expression of in vivo immune tumor resistance.

Authors:  E D Crum
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.